Prognostic factors of operated stage i non-small cell lung cancers: A tertiary center long-term outcomes
Haseki Tip Bulteni, cilt.59, sa.3, ss.221-227, 2021 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 59 Sayı: 3
- Basım Tarihi: 2021
- Doi Numarası: 10.4274/haseki.galenos.2021.6997
- Dergi Adı: Haseki Tip Bulteni
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.221-227
- Anahtar Kelimeler: Survival rate, carcinoma, non-small-cell lung, prognosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: This study aimed to evaluate prognostic factors influencing survival in patients who underwent surgical resection of Stage I non-small cell lung cancer (NSCLC) in our center. Methods: A total of 472 patients with Stage I NSCLC who were operated between January 2007 and November 2018 were retrospectively analysis in the study. Patient data was collected using hospital database. The remaining patients were divided into 2 groups: patients younger than 65 years of age (Group A) and those aged 65 and over (Group B). Results: The patient Group comprised 80 women (16.9%) and 392 men (83.1%); 152 patients were aged 65 years or over (32.2%) and 320 patients were under 65 years of age (81.5%). The mean follow-up time was 51 months. The 5-year survival rate was 67.2% overall. Patients with Stage IA1, IA2, IA3, and IB tumors had 5-year survival of 78.1%, 72.5%, 77.3%, and 56.7%, respectively (p=0.009). In multivariate analysis, advanced age (≥65 years), large cell carcinoma, left-sided surgery, and higher tumor Stage were the most important prognostic factors associated with poorer survival. Conclusion: Advanced age was determined to be an independent poor prognostic factor, and sub Group analyses showed that survival outcome was better with tumors smaller than 1 cm. Based on the results of our study, we believe that the classification of Stage I Group should be revised in the new edition of lung cancer staging.